AOD-9604 vs MOTS-c Side Effects: A Denominator Comparison

Side-Effect Lists Need Denominators

A list of reported events is interpretable only when the exposure, formulation, route, duration, population, ascertainment method, and number of participants are known. AOD-9604 and MOTS-c do not have comparable human evidence, so placing two lists side by side can create a false ranking.

FDA’s Office of Surveillance and Epidemiology made the point directly for AOD-9604:

“The lack of reports for AOD-9604 does not imply that the substance is safe or lacks toxicities.”

This 17-word excerpt comes from FDA’s December 2024 multidisciplinary evaluation. It addresses the limits of passive reports and sparse exposure, not proof that AOD-9604 causes a particular event or endorsement of another product (FDA AOD-9604 briefing, section II.D.2.b, PDF page 33).

The Evidence-Denominator Matrix

This matrix does not say the risks are equal. It says the evidence cannot measure the difference reliably.

What the AOD-9604 Human Record Shows

FDA reviewed a 2013 sponsor-linked publication summarizing six randomized, double-blind, placebo-controlled studies. The studies used oral or intravenous AOD-9604, not the proposed subcutaneous or transdermal compounded routes. FDA noted differences in design, population, duration, formulation, and missing case details (FDA AOD-9604 briefing, PDF pages 33–36; Stier et al., DOI 10.4021/jem157w).

In the small intravenous studies, reported events included headache, fatigue, dizziness, and unspecified hypoglycemia; chest tightness and euphoria were assessed as possibly related in individual reports. The oral studies reported headache, diarrhea, and flatulence among common events. Serious events in a 12-week oral study included several cancers that investigators judged unrelated, but FDA said the available detail was insufficient to resolve that assessment. This is not evidence that AOD-9604 caused cancer, and it is not a clean bill of safety.

The often-cited “536-person Phase IIb trial” enrolled 536 and randomized 502 adults with obesity to oral AOD-9604 or placebo. FDA reported that detailed methods and results were not published in the medical literature and that the study did not show significant weight loss at its primary endpoint. The number 536 should not be used to claim that a subcutaneous compounded product was proven safe or effective (FDA briefing, section II.C.2.a, PDF pages 24–26).

FDA’s current safety-risk page states that the AOD-9604 nomination was withdrawn and that compounded products may pose immunogenicity and impurity-characterization risks; causality for identified serious reports remains unclear (FDA, Certain Bulk Drug Substances That May Present Significant Safety Risks).

What the MOTS-c Record Shows

FDA’s July 2026 evaluation found no clinical studies or human exposure data for administered MOTS-c by any route. The cited human papers measured endogenous MOTS-c around exercise or across age groups; treatment findings came from cells and mice (FDA MOTS-c briefing, section II.D.2.c, PDF page 28; PMID 33473109).

A registered Phase 2a trial is recruiting adults with prediabetes and overweight or obesity, but it has no posted results (ClinicalTrials.gov NCT07505745). A future trial can add a denominator for its study product and population; it cannot retroactively validate products already sold under the same peptide name.

The MOTS-c rare-risk review separates FDA’s potential-risk assessment from events observed in humans.

Why Route and Product Identity Matter

An oral AOD-9604 exposure does not establish the safety of a subcutaneous preparation. Route changes bioavailability, local tissue exposure, immune presentation, and the relevance of sterility and particulate controls. FDA also noted that the free base and acetate are distinct bulk drug substances with potentially different physical, chemical, and pharmacologic properties.

The same logic applies to MOTS-c. A sequence name does not prove that two pharmacies produced the same concentration, impurity profile, aggregate burden, sterility, container performance, or stability. The MOTS-c storage audit explains why those attributes require product-specific evidence.

What the Comparison Can Responsibly Answer

• AOD-9604 has some administered-human oral and intravenous data, but the summaries are limited and do not cover the commonly proposed subcutaneous route.
• MOTS-c lacked administered-human exposure data in FDA’s July 2026 evaluation.
• Neither record supports an event-rate comparison for compounded injections.
• “Fewer reported side effects” may reflect less exposure, less surveillance, incomplete reporting, or a different route—not a safer substance.
• No current evidence establishes which product is safer for a particular person.

The middle-age MOTS-c evidence map shows why baseline risk and polypharmacy increase the need for direct data without creating a protocol.

Medical review of this revision is pending. FDA, sponsors, investigators, authors, trial registries, and institutions do not endorse AOD-9604, MOTS-c, HealthRX.com, or this page.